Brian Feagan shares the SELECTION study findings showing a role for filgotinib in the treatment of biologic-naive and experienced patients with moderately to severely active ulcerative colitis (10:21).
Silvio Danese discusses the STARDUST trial looking at the benefits of a treat-to-target strategy for optimising ustekinumab treatment in Crohn’s disease based on endoscopic and clinical outcomes (3:28).
Silvio Danese outlines the 52-week TRUE NORTH study findings showing the benefits of ozanimod in patients with moderate-to-severe ulcerative colitis (4:11).
Ryan Ungaro reports results from the updated SECURE-IBD registry looking at the impact patient characteristics and immunosuppressants have on COVID-19 outcomes in patients with IBD (5:45).
Peter Bossuyt discusses his pragmatic trial looking at the potential of ultraproactive therapeutic drug monitoring to improve infliximab dosing in patients with inflammatory bowel disease (5:38).
Patients who receive antiviral therapy for more than 90 days prior to hepatectomy for hepatitis B virus-related hepatocellular carcinoma have a reduced risk for microvascular invasion and early tumor recurrence, Chinese research shows.
Antibiotic therapy for Helicobacter pylori in patients with early gastric cancer is associated with a 50% lower risk for subsequent disease, trial findings indicate.
More than 290 million people, or 3.9% of the global population, are infected with hepatitis B virus, and while efforts to combat infection are improving, greater access to diagnosis and treatment is needed to meet global targets, report The Polaris Observatory Collaborators.
A high burden of metabolic risk factors significantly increases the risk for hepatocellular carcinoma among men with hepatitis B virus infection, particularly those who smoke, researchers from Taiwan report.
Follow medwireNews